Ninlaro (ixazomib) is now
NICE via the CDF:
NINLARO (ixazomib) with lenalidomide and dexamethasone (Rd) is recommended for use within the Cancer Drugs Fund (CDF) as an option for treating multiple myeloma (MM) in adults if they have already had 2 or 3 previous lines of therapy and the conditions of the managed access agreement for ixazomib are followed7
7. NICE Final Appraisal Determination - Ixazomib, with lenalidomide and dexamethasone for relapsed
or refractory multiple myeloma.
https://www.nice.org.uk/guidance/indevelopment/gid-ta10043 Accessed December 2017